Synthetic bacterial consortia transplantation attenuates vaginal inflammation and modulates the immune response in a mouse model of Gardnerella vaginalis-induced bacterial vaginosis
- PMID: 39498013
- PMCID: PMC11533556
- DOI: 10.1016/j.heliyon.2024.e38218
Synthetic bacterial consortia transplantation attenuates vaginal inflammation and modulates the immune response in a mouse model of Gardnerella vaginalis-induced bacterial vaginosis
Abstract
This study aimed to evaluate the efficacy of synthetic bacterial consortia transplantation (SBCT) and compare it with VMT (vaginal microbiota transplantation) in a mouse model of Gardnerella vaginalis-induced Bacterial vaginosis (BV). A murine model of G. vaginalis-induced BV was established, and mice were treated with SBCT, VMT, or saline. Histopathological changes, inflammatory cytokine levels, pro-inflammatory biomarker expression, helper T cell transcription factor expression, and vaginal microbiota composition were assessed. SBCT and VMT effectively suppressed G. vaginalis growth, reduced inflammation, and restored vaginal microbiota diversity. Both treatments attenuated epithelial damage, downregulated pro-inflammatory cytokines (IL-1β and IL-8), and upregulated the anti-inflammatory cytokine IL-10. SBCT and VMT also inhibited NF-κB activation, suppressed IL-17 expression, and enhanced Foxp3 expression in vaginal tissues. SBCT is a promising therapeutic approach for treating BV, as it effectively modulates the immune response and restores vaginal microbiota diversity in a mouse model of G. vaginalis-induced BV.
Keywords: Bacterial vaginosis; Gardnerella vaginalis; Immune response; Inflammation; Synthetic bacterial consortia transplantation; Vaginal microbiota transplantation.
© 2024 Published by Elsevier Ltd.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures






Similar articles
-
Synthetic bacterial consortia transplantation for the treatment of Gardnerella vaginalis-induced bacterial vaginosis in mice.Microbiome. 2023 Mar 20;11(1):54. doi: 10.1186/s40168-023-01497-y. Microbiome. 2023. PMID: 36941732 Free PMC article.
-
Lactobacillus johnsonii HY7042 ameliorates Gardnerella vaginalis-induced vaginosis by killing Gardnerella vaginalis and inhibiting NF-κB activation.Int Immunopharmacol. 2011 Nov;11(11):1758-65. doi: 10.1016/j.intimp.2011.07.002. Epub 2011 Jul 26. Int Immunopharmacol. 2011. PMID: 21798373
-
Development of the standard mouse model for human bacterial vaginosis induced by Gardnerella vaginalis.Front Vet Sci. 2023 Sep 12;10:1226859. doi: 10.3389/fvets.2023.1226859. eCollection 2023. Front Vet Sci. 2023. PMID: 37781285 Free PMC article.
-
The effectiveness of vaginal microbiota transplantation for vaginal dysbiosis and bacterial vaginosis: a scoping review.Arch Gynecol Obstet. 2024 Aug;310(2):643-653. doi: 10.1007/s00404-024-07611-1. Epub 2024 Jun 24. Arch Gynecol Obstet. 2024. PMID: 38914708
-
The Female Vaginal Microbiome in Health and Bacterial Vaginosis.Front Cell Infect Microbiol. 2021 Apr 7;11:631972. doi: 10.3389/fcimb.2021.631972. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 33898328 Free PMC article. Review.
Cited by
-
Population-level analyses identify host and environmental variables influencing the vaginal microbiome.Signal Transduct Target Ther. 2025 Feb 19;10(1):64. doi: 10.1038/s41392-025-02152-8. Signal Transduct Target Ther. 2025. PMID: 39966341 Free PMC article.
References
-
- Das S., Bhattacharjee M.J., Mukherjee A.K., Khan M.R. Recent advances in understanding of multifaceted changes in the vaginal microenvironment: implications in vaginal health and therapeutics. Crit. Rev. Microbiol. 2023;49:256–282. - PubMed
-
- Ahrodia T., Yodhaanjali J.R., Das B. Vaginal microbiome dysbiosis in preterm birth. Prog Mol Biol Transl Sci. 2022;192:309–329. - PubMed
LinkOut - more resources
Full Text Sources